Barbara Jungwirth is an experienced freelance journalist, writer, and translator who has been reporting on HIV for TheBody and TheBodyPro since 2002. Specializing in technical summaries of published and presented research on HIV and related topics, Barbara has been the primary author of TheBodyPro's "This Week in HIV Research" series since 2014.
Latest by Barbara Jungwirth
Sept. 12, 2019: Better virologic outcomes at coordinated walk-in facilities offering incentives; same-day PrEP initiation at STD clinics; U=U and "low drug regimens"; adherence trends among perinatally infected adolescents.
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.
Communities Should Be Involved in Research. Here Are Some Key Insights on Good Participatory Practice.
Increasingly, researchers are looking for ways to involve communities not just by participating in trials, but by helping shape these projects. But, how do you go about making sure affected communities are at the table?
Recent Trump administration policies on migrants living with HIV have prompted a response from the international AIDS research community.
Nonjudgmental services and innovative ways to talk to youth about sex should be at the core of any sexual health plan.
Aug. 22, 2019: Links between thiamine deficiency and cognitive issues; HIV in cerebrospinal fluid and neurocognitive impairment; frailty, depression, and symptomatic cognitive issues; alcohol consumption and HIV disease progression.
"We have never been silent, but you have not heard us": Advocates demonstrate to demand inclusion of indigenous issues in the HIV response.
Aug. 15, 2019: PCP continuity, ID specialization, and adherence; rules of HIV patient engagement; long-term benefits of financial incentives on adherence; headaches and TDF/FTC.
Four recent studies in JAIDS chiefly focused on PrEP provision to cisgender women and gay and bisexual men.